• 1
    Page NC, Read WL, Tierney RM, et al. The epidemiology of small cell lung carcinoma [abstract 1216]. Proc Am Soc Clin Oncol. 2002; 21: 305a.
  • 2
    Simon RS, Wagner H. Small cell lung cancer. Chest. 2003; 123: 259S271S.
  • 3
    Sandler A. Chemotherapy for small-cell lung cancer. Semin Oncol. 2003; 30: 925.
  • 4
    Schiller J, Adak S, Cella D, et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small cell lung cancer: E7593-a Phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2001; 19: 21142122.
  • 5
    Hanna NH, Sandler AB, Loehrer PJ, et al. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann Oncol. 2002; 13: 95102.
  • 6
    Steward WP, von Pawel J, Gatzemeier U, et al. Effects of granulocyte colony-stimulating factor and dose-intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. J Clin Oncol. 1998; 16: 642650.
  • 7
    Thatcher N, Girling DJ, Hopwood P, et al. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council multicenter randomized trial. J Clin Oncol. 2000; 18: 395404.
  • 8
    Sculier JP, Paesmans M, Lecomte J, et al. A three arms Phase III randomized trial assessing, in patients with extensive-disease small cell lung cancer, accelerated chemotherapy with support of hematological growth factor or oral antibiotics. Br J Cancer. 2001; 85: 14441451.
  • 9
    Ettinger DS. New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer. Semin Oncol. 2001; 28(2 Suppl. 4 ): 2729.
  • 10
    Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002; 346: 8591.
  • 11
    Reck M, von Pawel J, Macha HN, et al. Randomized Phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer. J Natl Cancer Inst. 2003; 95: 11181127.
  • 12
    Cormier Y, Eisenhauer E, Muldal A, et al. Gemcitabine is an active new agent in previously untreated extensive-stage small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 1994; 5: 283285.
  • 13
    Masters GA, Declerck L, Blande C, et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol. 2003; 21: 15501555.
  • 14
    De Marinis F, Migliorino MR, Paoluzzi L, et al. Phase I/II trial of gemcitabine plus cisplatin and etoposide in patients with small-cell lung cancer. Lung Cancer. 2003; 39: 331338.
  • 15
    Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981; 47: 207214.
  • 16
    Simon R. Optimal two-stage designs for Phase II clinical trials. Control Clin Trials. 1989; 10: 110.
  • 17
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 18
    Bunn PA. Chemotherapy for advanced non-small cell lung cancer: who, what, when, why? J Clin Oncol. 2002; 20: 23S33S.
  • 19
    Sandler A, Langer C, Bunn PA, et al. Interim safety analysis of irinotecan and cisplatin combination chemotherapy for previously untreated extensive stage small cell lung cancer [abstract 2537]. Proc Am Soc Clin Oncol. 2003; 22: 631a.
  • 20
    Mavroudis D, Papadakis E, Veslemes M, et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol. 2001; 12: 463470.
  • 21
    Niell HB, Herndon JE, Miller AA, et al. CALGB 9732: final report of a randomized Phase III intergroup trial of etoposide (VP-16) and cisplatin (DDP) with or without paclitaxel (TAX) and G-CSF in patients with extensive stage small cell lung cancer (ED-SCLC) [abstract 277]. Lung Cancer. 2003; 41( Suppl 2): S81.
  • 22
    Trodella L, Granone P, Valente S, et al. Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small cell lung cancer. J Clin Oncol. 2002; 20: 804810.
  • 23
    Rudd RM, Gower NH, James LE, et al. Phase III randomized comparison of gemcitabine/carboplatin (GC) with cisplatin/etoposide (PE) in patients with poor prognosis small cell lung cancer (SCLC) [abstract 1170]. Proc Am Soc Clin Oncol. 2003; 21: 293a.